ReviewFrontiers in molecular biosciences2026
Succinylation: novel molecular mechanisms and prospects for targeted therapy in liver diseases.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Succinylation is a novel post-translational modification involving the attachment of a negatively charged succinyl group to lysine residues, which fundamentally alters the structure and function of substrate proteins. The liver, the metabolic center of the body, is a critical target for succinylation because of its high metabolic activity. Growing evidence suggests that succinylation is a core pathological mechanism that bridges hepatic metabolic dysfunction and disease progression by modulating metabolic enzyme activity, influencing epigenetic status, and remodeling the immune microenvironment. This review aimed to systematically outline the molecular features and regulatory networks of succinylation, dissect its mechanistic roles in major liver diseases, and synthesize current therapeutic strategies, including clinical drug repurposing, small-molecule agents, and traditional Chinese medicinal compounds that target this modification. Collectively, these insights offer a novel theoretical framework and promising therapeutic direction for the management of liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.